Pharmaceutical industry – Page 48
-
Business
AstraZeneca claims quashed in heartburn drug patent case
Nexium rival does not infringe on patent, court rules
-
Business
Chinese police seize £222m of fake drugs
1300 people are arrested in a nationwide crackdown on counterfeit medicines
-
Business
AstraZeneca shells out $4.1bn for diabetes business
Bristol-Myers Squibb exits the diabetes field with plans to become a specialised biopharmaceutical company
-
Opinion
Cut price pills cost more than pennies
We can’t afford to let the demand for cheaper medicines force compromises on quality, says Steven Ford
-
Business
New wave of hepatitis C drugs hits US shore
J&J’s once-daily drug approved by FDA, but rivals are hot on its heels
-
Business
US turnaround on Avandia restrictions
Researchers accuse regulator of face-saving U-turn over diabetes medication safety
-
Opinion
Put the chemistry back in medicinal chemistry
Pursuing skewed priorities and easy options has impoverished the pharmaceutical industry, says David Lathbury.
-
Opinion
Rolling boulders uphill
Is Derek Lowe troubled by his failure to develop a compound that has made it to the pharmacy shelf?
-
Business
Regulator cracks down on 23andMe
Personal genetic profiler ordered to stop selling DNA test kits
-
Business
Pfizer teams up with GSK in cancer drug trial
Two companies will collaborate to develop a combination therapy for melanoma
-
Feature
Generic problems
The Indian pharmaceutical industry has been hit by recent problems. Angeli Mehta investigates
-
Business
DSM to spin out pharma unit
Firm will combine with Patheon to provide manufacturing services
-
Business
Novartis sells off blood diagnostics division
$1.7bn deal reinforces firm’s focus on core pharmaceuticals
-
Careers
The pain killer
Life is pretty painless working in Reckitt Benckiser’s Nurofen team, Sarah Houlton learns
-
Business
Shire will cut UK R&D to focus on rare diseases
$4.2bn buyout of ViroPharma bolsters pipeline, while Basingstoke site halts research
-
Business
Mis-selling lands J&J with $2.2bn fine
Company found guilty of promoting three drugs for unapproved uses
-
Business
Novartis to shut Horsham site
UK research centre closure to result in the loss of 371 jobs as firm consolidates its global R&D base
-
Opinion
Natural born chemists
Redesigning nature’s catalysts is tantalising but tricky, says Derek Lowe